4 reports

TREGALIZUMAB IS ANOTHER HIGH-RISK PHASE II INVESTIGATIONAL DRUG, AN ANTI-CD## MONOCLONAL ANTIBODY, INDUCING SELECTIVE ACTIVATION OF REGULATORY T-CELLS.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatology
  • Monoclonal Antibody
  • Immune Pharmaceuticals Inc.
  • Feb 20, 2018: Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

Its Bertilimumab is a human monoclonal antibody designed to block the protein eotaxin-## which causes various diseases.

  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Company
  • Immune Pharmaceuticals Inc.
  • Feb 20, 2018: Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

Bertilimumab is a first-in-class, humanized monoclonal antibody that targets and lowers eotaxin-## levels in many inflammatory conditions.

  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Company
  • Immune Pharmaceuticals Inc.
  • Immune Pharmaceuticals Inc. - Preclinical, 2016

The drug candidate is a human immunoglobulin monoclonal antibody targeting eotaxin-##.

  • Monoclonal Antibody
  • United States
  • World
  • Company Operations
  • Immune Pharmaceuticals Inc.